Stem definition | Drug id | CAS RN |
---|---|---|
androgens/anabolic steroids | 3356 | 58-18-4 |
Dose | Unit | Route |
---|---|---|
25 | mg | O |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
S (Water solubility) | 0.03 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 3, 1973 | FDA | VALEANT PHARM INTL |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | G03BA02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS 3-oxoandrosten (4) derivatives |
ATC | G03EA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION Androgens and estrogens |
ATC | G03EK01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION Androgens and female sex hormones in combination with other drugs |
FDA CS | M0001109 | Androstanes |
FDA MoA | N0000000146 | Androgen Receptor Agonists |
MeSH PA | D045930 | Anabolic Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
MeSH PA | D006728 | Hormones |
FDA EPC | N0000175824 | Androgen |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50113 | androgene |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Deficiency of testosterone biosynthesis | indication | 38825009 | |
Inhibition of lactation procedure | indication | 43141007 | |
Male hypogonadism | indication | 48723006 | |
Menopausal flushing | indication | 198436008 | |
Delayed puberty | indication | 400003000 | |
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Primary Hypogonadism due to Orchitis | indication | ||
Primary Hypogonadism due to Bilateral Torsion | indication | ||
LHRH Deficiency | indication | ||
Bilateral Anorchia | indication | ||
Undescended testicle | off-label use | 204878001 | DOID:11383 |
Noonan's syndrome | off-label use | 205824006 | DOID:3490 |
Klinefelter's syndrome, XXY | off-label use | 405769009 | |
Hyperlipoproteinemia | contraindication | 3744001 | DOID:1168 |
Hypocalcemia | contraindication | 5291005 | |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Chloasma | contraindication | 36209000 | |
Migraine | contraindication | 37796009 | DOID:6364 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Body fluid retention | contraindication | 43498006 | |
Thrombosis of retinal vein | contraindication | 46085004 | |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Dementia | contraindication | 52448006 | |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Heart failure | contraindication | 84114007 | DOID:6000 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Breast lump | contraindication | 89164003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
Neoplasm of liver | contraindication | 126851005 | DOID:3571 |
Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
Deep venous thrombosis | contraindication | 128053003 | |
Endometriosis | contraindication | 129103003 | |
Mammography abnormal | contraindication | 168750009 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Cerebrovascular accident | contraindication | 230690007 | |
Pulmonary thromboembolism | contraindication | 233935004 | |
Thrombophilia | contraindication | 234467004 | DOID:2452 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Edema | contraindication | 267038008 | |
Chorea | contraindication | 271700006 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Functional visual loss | contraindication | 313165001 | |
Malignant tumor of ovary | contraindication | 363443007 | DOID:2394 |
Thromboembolic disorder | contraindication | 371039008 | |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Estrogen receptor positive tumor | contraindication | 416053008 | |
Family history of malignant neoplasm of breast | contraindication | 429740004 | |
Hypertensive urgency | contraindication | 443482000 | |
Carcinoma of female breast | contraindication | 447782002 | |
Smokes tobacco daily | contraindication | 449868002 | |
Breast Carcinoma in Males | contraindication |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Androgen receptor | Nuclear hormone receptor | AGONIST | EC50 | 9.66 | IUPHAR | CHEMBL | |||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 6.08 | DRUG MATRIX | |||||
Sex hormone-binding globulin | Secreted | Kd | 8.43 | CHEMBL | |||||
Androgen receptor | Transcription factor | IC50 | 7.80 | CHEMBL | |||||
Progesterone receptor | Transcription factor | Ki | 7.48 | DRUG MATRIX |
ID | Source |
---|---|
4017433 | VUID |
N0000145821 | NUI |
D00408 | KEGG_DRUG |
4017433 | VANDF |
C0025826 | UMLSCUI |
CHEBI:27436 | CHEBI |
CHEMBL1395 | ChEMBL_ID |
D008777 | MESH_DESCRIPTOR_UI |
DB06710 | DRUGBANK_ID |
6945 | IUPHAR_LIGAND_ID |
399 | INN_ID |
V9EFU16ZIF | UNII |
6010 | PUBCHEM_CID |
6904 | RXNORM |
1048 | MMSL |
5096 | MMSL |
d00295 | MMSL |
001249 | NDDF |
126161000 | SNOMEDCT_US |
42348003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
MethylTESTOSTERone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1408 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
METHITEST | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-7037 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
COVARYX | HUMAN PRESCRIPTION DRUG LABEL | 2 | 11528-010 | TABLET, COATED | 2.50 mg | ORAL | unapproved drug other | 14 sections |
COVARYXHS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 11528-020 | TABLET, COATED | 1.25 mg | ORAL | unapproved drug other | 14 sections |
Esterified Estrogen and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13925-180 | TABLET | 1.25 mg | ORAL | unapproved drug other | 22 sections |
Esterified Estrogen and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13925-181 | TABLET | 2.50 mg | ORAL | unapproved drug other | 22 sections |
EEMT | HUMAN PRESCRIPTION DRUG LABEL | 2 | 15310-010 | TABLET, COATED | 2.50 mg | ORAL | unapproved drug other | 13 sections |
EEMTHS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 15310-020 | TABLET, COATED | 1.25 mg | ORAL | unapproved drug other | 13 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50220-001 | TABLET, FILM COATED | 1.25 mg | ORAL | Unapproved drug other | 13 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50220-002 | TABLET, FILM COATED | 2.50 mg | ORAL | Unapproved drug other | 13 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51293-639 | TABLET | 1.25 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51293-639 | TABLET | 1.25 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51293-640 | TABLET | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51293-640 | TABLET | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53746-077 | TABLET | 1.25 mg | ORAL | unapproved drug other | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53746-077 | TABLET | 1.25 mg | ORAL | unapproved drug other | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53746-078 | TABLET | 2.50 mg | ORAL | unapproved drug other | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53746-078 | TABLET | 2.50 mg | ORAL | unapproved drug other | 14 sections |
ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 58657-405 | TABLET | 2.50 mg | ORAL | unapproved drug other | 18 sections |
ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 58657-405 | TABLET | 2.50 mg | ORAL | unapproved drug other | 18 sections |
ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 58657-406 | TABLET | 1.25 mg | ORAL | unapproved drug other | 18 sections |
ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 58657-406 | TABLET | 1.25 mg | ORAL | unapproved drug other | 18 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 62559-149 | TABLET | 2.50 mg | ORAL | Unapproved drug other | 27 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 62559-150 | TABLET | 1.25 mg | ORAL | Unapproved drug other | 27 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-1979 | TABLET | 2.50 mg | ORAL | Unapproved drug other | 27 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-1979 | TABLET | 2.50 mg | ORAL | Unapproved drug other | 27 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-1980 | TABLET | 1.25 mg | ORAL | Unapproved drug other | 27 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-1980 | TABLET | 1.25 mg | ORAL | Unapproved drug other | 27 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-9177 | TABLET | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |
Esterified Estrogens and Methyltestosterone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-9177 | TABLET | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 14 sections |